Drug Development
Therapeutic Pipeline
Ion channel-targeted non-opioid therapeutic pipeline. Candidates discovered through our RuCIA platform are advancing into global clinical trials.
RCI001
Target: TRPV1-Rac1 Downstream Modulator
Unlike direct TRPV1 channel antagonists, RCI001 modulates the TRPV1 downstream Rac1/NLRP3 inflammatory cascade — restoring tear film homeostasis and corneal epithelial healing without blocking thermosensation. Differentiated MoA addresses root inflammatory cause, not just symptoms.
Key Details
- •Differentiated MoA: downstream signal modulator (not a direct TRPV1 antagonist)
- •Global development: US FDA Phase 2 + Korea Phase 2 (2026)
- •0.25% topical ophthalmic solution — non-steroidal, well-tolerated
- •Sjögren's syndrome model: tear secretion increase within 1 week
- •Therapeutic onset within 4 weeks (vs 8-12 weeks for steroid alternatives)
- •Overcomes steroid side effects: no IOP elevation, no redness, no burning
- •Avoids thermosensation blockade common to first-gen TRPV1 antagonists
- •TRPV1 active-disease treatment patents granted in Korea, Japan, US
Milestones
RCI002
Target: TRPV1-MOR Biased Dual Target
MOR biased dual-target non-opioid analgesic simultaneously modulating TRPV1 and MOR — preparing CRPS Orphan Drug Designation
Key Details
- •Indications: CRPS, OA, diabetic neuropathy, CIPN, fibromyalgia
- •MOR biased agonism minimizes addiction/tolerance risk
- •Single dose: 2+ weeks pain reduction in OA model
- •No abnormal fever side effect (solved 1st-gen TRPV1 issue)
- •Efficacy at 650x lower concentration vs existing treatments
- •FDA Orphan Drug Designation (ODD) for CRPS in preparation
Milestones
RCI003
Target: Selective Modulator of Psoriasis Target Proteins
AI drug platform-based selective modulation of psoriasis target proteins — leveraging TRPV1 ion channel expertise
Key Details
- •Syntekabio AI platform (STB) for target protein analysis
- •RudaCure TRPV1 expertise applied to skin disease ion channels
- •Sogang University: compound synthesis & optimization
- •Inje University: candidate compound efficacy evaluation
- •Research period: Apr 2026 – Mar 2028
Milestones
RCI0165
Target: TRPV1 Only Target (AAV Vector)
AAV vector-based TRPV1-targeted gene therapy — single administration for long-term pain relief in animals
Key Details
- •AAV (Adeno-Associated Virus) vector-based gene therapy
- •TRPV1 ion channel single target (only target)
- •Single administration provides 3+ months sustained pain relief
- •For chronic pain management in companion animals and high-value animals (racehorses)
- •Global veterinary pain treatment market ~$2B annually
Milestones
RC0125 AAV
Target: TRPV4 Intracellular Target (AAV Vector)
AAV vector-based gene therapy targeting intracellular TRPV4 — developed as an orphan drug with plans to expand to related diseases
Key Details
- •AAV vector-based gene therapy targeting intracellular TRPV4 channel
- •Proven analgesic efficacy in osteoarthritis (OA) animal models
- •Currently undergoing candidate drug optimization
- •Initial development targets rare orphan disease CMT2C, with plans for expansion to related disorders